Clinical Trials in Detroit

Showing 7741-7760 of 14,997 trials

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NCT01960023

The FC-7 study is designed as an open label, single arm, Phase I/II dose-escalation study evaluating the combination of neratinib and cetuximab in patients with metastatic colorectal cancer primary tumor that is "quadruple wild-type " (wild-type KRAS, NRAS, BRAF, PIK3CA). The primary aim in the Phase I portion of this study is to determine the safety and tolerability of the two-drug combination. The primary aim of the Phase II part is to determine the overall objective response rate (complete and partial responses) by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Patients will receive concurrent therapy with cetuximab (400 mg/m2 IV loading dose followed by 250 mg/m2 IV weekly), and neratinib.

Colorectal Cancer

NSABP Foundation IncStarted Oct 2013

Gainesville, Florida, United States • Orlando, Florida, United States • Boise, Idaho, United States +9 more locations

COMPLETEDPhase 3< 1 mile

Tolvaptan Extension Study in Participants With ADPKD

NCT01214421

To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Otsuka Pharmaceutical Development & Commercialization, Inc.1,083 participantsStarted May 2010

Mobile, Alabama, United States • Peoria, Arizona, United States • Tempe, Arizona, United States +94 more locations

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

Tolvaptan Extension Study in Participants With ADPKD

Find Trials by Condition in Detroit

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

An Integrated Program for the Treatment of First Episode of Psychosis

Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

B Cell Induction in Pediatric Lung Transplantation

Study of AMV564 in Subjects With Advanced Solid Tumors

Triathlon Total Stabilizer (TS) Outcomes Study

A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ